



ACN 626 295 314

12 June 2020

Dear Shareholders,

The Company's annual general meeting of shareholders is scheduled to be held in Sydney, NSW on 14 July 2020 at 4.00 pm (EST) (**Meeting**).

In accordance with subsection 5(f) of the Corporations (Coronavirus Economic Response) Determination (No. 1) 2020, the Company will not be dispatching physical copies of the Notice of Meeting (**NOM**). Instead, a copy of the NOM can be viewed and downloaded online at the following link:

<https://web.automic.com.au/er/public/api/documents/HMD?fileName=HMDNoticeAGM2020.pdf>

Due to the evolving COVID-19 situation and the implementation by the Australian Government of restrictions on public gatherings and social distancing measures, at the date of this Notice Shareholders will not be able to attend the Meeting in person.

All resolutions will be decided on a poll. The poll will be conducted based on votes submitted by proxy and at the Meeting by shareholders who have indicated that they intend to vote at the Meeting in accordance with the instructions set out below.

The Directors instruct all shareholders who would like to have their vote counted to either:

- **vote by lodging a proxy form prior to 12 July 2020 at 4.00 pm (EST) (Proxy Cut-Off Time) (recommended); or**
- **Shareholders who wish to participate and vote at the Meeting should contact the Company at jonathan@hera-med.com or by phone at (02) 8379 2961 prior to 4.00 pm (EST) on 12 July 2020, at which point the Company will email you a personalised poll form for the purpose of voting on a poll at the Meeting.**

How Shareholders can participate:

1. Shareholders are strongly urged to appoint the Chair of the Meeting as their proxy. Shareholders can complete the proxy form to provide specific instructions on how a Shareholder's vote is to be cast on each item of business, and the Chair of the Meeting must follow your instructions. Lodgement instructions (which include the ability to lodge proxies online) are set out in the Proxy Form attached to the Notice of Meeting. If a person other than the Chair is appointed as proxy, the proxy will revert to the Chair in the absence of the appointed proxy holder's attendance at the meeting.
2. Shareholders who intend to participate and vote on a poll at the Meeting must contact the Company at jonathan@hera-med.com or by phone at (02) 8379 2961 to notifying the Company that you intend to participate and vote on a poll at the Meeting by emailing the Company a poll form. You will also need to register and access the Meeting by teleconference to follow the meeting and timing of the poll. After giving notice and following the Proxy Cut-Off Time, the Company will send you a personalised poll form. The personalised poll form must be completed and returned to the Company after the poll has been called and **prior to the close of polling**. During the Meeting, the Chair will

For personal use only

notify you when and how you are able to complete and return the personalised poll form. The results of the Meeting will then be announced on the ASX later today.

3. Shareholders who have completed a proxy form but have not notified the Company that you intend to participate and vote on a poll at the Meeting will have an opportunity to participate in the meeting through the teleconference facility described in item 5 below. In this circumstance, the person you have appointed as proxy will cast your vote on your behalf.
4. The Meeting will be accessible to all Shareholders via a live teleconference, which will allow a Shareholder to listen and observe the Meeting.

Register in advance for this webinar:

https://us02web.zoom.us/webinar/register/WN_jzTTMDhdTKybpafSdaE3nw

After registering, you will receive a confirmation email containing information about joining the webinar.

The situation is constantly evolving and accordingly we may make alternative arrangements to the way in which the Meeting is held. If this occurs, we will notify any changes by way of announcement on ASX and the details will also be made available on our website. The Notice is important and should be read in its entirety. If you are in doubt as to the course of action you should follow, you should consult your financial adviser, lawyer, accountant or other professional adviser.

This announcement is authorised for market release by the board of Directors of HeraMED Limited.

Yours sincerely

Jonathan Hart
Company Secretary